Pershing Square Foundation funds SARS-CoV-2 research
The Pershing Square Foundation has awarded $3 million to 19 researchers investigating the novel coronavirus. Read More
Li-Cor supports virology research for COVID-19
Li-Cor Biosciences offers research solutions for therapeutics development and western blotting. Now, the company is offering researchers a special Odyssey Clx Viral Solution package at a reduced price to support COVID-19 research. Read More
Horizon Discovery accelerates CRISPR gene editing workflows
Horizon Discovery Group has introduced a new stably expressing Cas9 cell line for knockout experiments and a dCas9-VPR cell line for gene activation experiments. Read More
CytoAgents advances COVID-19 cytokine storm inhibitor
CytoAgents will accelerate development of its lead COVID-19 drug candidate, GP1681, with an investment from the Richard King Mellon Foundation. Read More
Aboundbio licenses COVID-19 antibodies to SaudiVax
Aboundbio has inked an agreement with SaudiVax for the production and clinical development of neutralizing antibodies against SARS-CoV-2. Read More
BARDA awards supply contract to Regeneron for COVID-19 cocktail
Regeneron Pharmaceuticals was awarded a $450 million contract to manufacture and supply its REGN-COV2 antibody cocktail that is currently in phase II/III clinical trials for the treatment of COVID-19 patients and phase III for the prevention of COVID-19. Read More
Tessera introduces new genome engineering strategy
Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing technology to cure diseases. Read More
Parkinson's Foundation releases results of PD Generation study
The Parkinson's Foundation announced the preliminary results from its Parkinson's Disease (PD) Generation: Mapping the Future of PD pilot study. Read More
Regeneron begins COVID-19 antibody treatment phase III trial
Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention of COVID-19. Read More
Medivir, SciLifeLab partner on SARS-CoV-2 inhibitors
Medivir, a Swedish pharmaceutical company, is partnering with SciLifeLab, a Swedish national research laboratory, to leverage their drug discovery and development platform to find potential inhibitors of SARS-CoV-2. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
